Health · Pharma & Biotech · 11 hrs ago
Experimental CBL-514 injection may reduce fat, but safety questions remain
CBL-514 is an experimental injection designed to make fat cells break down, rather than just shrink.
It works differently from drugs such as semaglutide and tirzepatide, which reduce appetite.
In a phase-two study of 108 adults, under-skin belly fat fell by just over 20% on average four weeks after treatment, while it barely changed with a placebo.
A separate analysis of MRI scans from 41 participants found fat around the organs fell by 12% on average, while it rose in the placebo group.
This deep abdominal fat is linked to higher risks of type 2 diabetes and heart disease, but the analysis is small and has not yet been published in a peer-reviewed journal.
Researchers say the early results do not show whether CBL-514 helps people lose weight or improves health, and larger studies with longer follow-up are needed.
Animal experiments raise the possibility that it could limit weight regain after stopping a weight-loss drug, but this has not been shown in people.
Possible liver side effects remain a concern, and the available evidence does not establish whether the treatment is safe or effective.
Experimental injection CBL-514 is designed to trigger the controlled death of fat cells rather than simply shrink them.
A phase-2 study found that under-the-skin abdominal fat fell by an average of just over 20% four weeks after treatment.
A separate analysis of MRI scans found an average 12% reduction in visceral fat, but it involved only 41 participants and has not been fully peer-reviewed.
Researchers say the findings do not show whether CBL-514 helps people lose weight or improves their health.
Possible liver side effects remain a concern, and larger studies with longer follow-up are needed.
- Who
- Caliway Biopharmaceuticals is developing CBL-514; the studies involved adults with a BMI of 22 to 30.
- What
- The experimental injection may reduce under-the-skin and visceral fat by triggering fat-cell apoptosis.
- When
- The article was published on 19 October 2026. Measurements were reported four weeks after the last treatment.
- Where
- The injections were given in the abdomen; study findings were presented at the European Association for the Study of Diabetes congress.
- Why
- The treatment is intended to reduce fat directly by prompting fat cells to undergo controlled cell death.
This story does not have two clearly opposing sides.
Under-the-skin fat in the CBL-514 group was down by an average of just over 20%, while the placebo group showed almost no change.
In an analysis of 41 participants, visceral fat in the CBL-514 group was down by an average of 12%, while it rose by 5.7% in the placebo group.
The difference in visceral fat between the CBL-514 and placebo groups remained.
- Phase-2 under-the-skin fat study
- 108 adults
- Under-the-skin fat reduction
- Just over 20% on average, four weeks after the last treatment
- Visceral fat analysis
- 41 participants
- Visceral fat change
- Down 12% with CBL-514; up 5.7% with placebo
- Developer
- Caliway Biopharmaceuticals
What people are saying
These results provide encouraging initial evidence that CBL-514 can reduce the volume of visceral fat in the abdomen
These results in humans do not show whether the treatment helps people lose weight or improves their health